
Shimadzu Corporation
Japanese precision instruments manufacturer founded in 1875, listed on the Tokyo Stock Exchange (7701) with 560.7 billion yen in FY2025 sales across analytical, medical, industrial, and aircraft segments.
Company Type
public
Founded
1875
Headquarters
Kyoto, Kyoto, Japan
Stock
Tokyo Stock Exchange: 7701
Revenue
560.7 billion yen (FY2025)
Employees
14,649 (group, as of March 2026)
Primary Market
Global
About Shimadzu Corporation
Who owns Shimadzu Corporation?
It is publicly owned through its listing on the Tokyo Stock Exchange, code 7701. Shareholders are institutional investors, trust banks, foreign funds, and individuals; no family or single holder controls it.
Is Shimadzu Corporation publicly traded?
Yes. It has long been listed on the Tokyo Stock Exchange and publishes quarterly consolidated results under Japanese GAAP.
What does Shimadzu Corporation make?
Analytical and measuring instruments such as chromatographs and mass spectrometers, medical X-ray and imaging systems, industrial machinery including turbomolecular pumps, and aircraft equipment.
When was Shimadzu founded?
In March 1875 in Kyoto by Genzo Shimadzu, originally to produce physics and chemistry educational instruments. It incorporated as a limited company in 1917 and marked its 150th anniversary in 2025.
How large is Shimadzu?
Fiscal 2025 consolidated net sales were 560.7 billion yen, about $3.6 billion, with 14,649 group employees and 77 subsidiaries worldwide as of March 2026.
Did Shimadzu win a Nobel Prize?
An employee did. Engineer Koichi Tanaka shared the 2002 Nobel Prize in Chemistry for soft laser desorption ionization, the technology behind MALDI-TOF mass spectrometry.
History of Shimadzu Corporation
Genzo Shimadzu founded the company in Kyoto in March 1875, eight years into the Meiji restoration, as Japan industrialized and built a modern education system. His workshop produced physics and chemistry teaching instruments and scientific specimens for schools, earning an early reputation for precision that became the firm's identity.
The founder's son, who also took the name Genzo, drove the first major pivot. In 1896, months after Wilhelm Roentgen's discovery of X-rays, the company produced one of the first X-ray images made in Japan, establishing a medical systems business that still operates today. Shimadzu incorporated as a limited company in September 1917.
Through the twentieth century the company built the analytical instruments franchise that now generates most of its revenue. It commercialized spectrophotometers, gas chromatographs, liquid chromatographs, and eventually mass spectrometers, rising to become Japan's dominant maker of laboratory measurement equipment and a global challenger to American and European instrument houses.
Diversification followed the same precision-engineering logic. Industrial machinery grew around turbomolecular pumps, hydraulic components, and semiconductor manufacturing equipment. An aircraft equipment business developed flight management systems, cockpit displays, and control components, largely serving Japanese defense and commercial aerospace programs.
The 2002 Nobel Prize in Chemistry, shared by Shimadzu engineer Koichi Tanaka for his invention of soft laser desorption ionization, was a defining moment: the technique enabled MALDI-TOF mass spectrometry and remains the most celebrated example of an industrial researcher winning science's highest honor.
Through the 2010s and 2020s, the company executed steady growth in life sciences, healthcare, and semiconductor-adjacent markets. Net sales set records for five consecutive fiscal years, reaching 560.7 billion yen in fiscal 2025, which ended March 2026. The company marked its 150th anniversary in 2025 and is executing a medium-term plan targeting 620 billion yen in sales for fiscal 2026.
Shimadzu Corporation Sustainability & Ethics
Shimadzu publishes an integrated annual report and operates under a formal Sustainability Charter framed around solving societal challenges through its businesses and acting as a responsible corporate member. Climate disclosure follows Japanese exchange requirements, and the company reports progress on operational carbon reduction and product energy efficiency.
Material social programs center on human capital under a "Leadership and Diversity" framework, R&D employment of advanced-degree researchers, and quality and safety systems appropriate to medical and aerospace customers. It is not B Corp certified, as is normal in its industry, and its medical and defense-adjacent segments carry the compliance regimes those markets require.
Awards & Recognition
The company's most distinguished recognition is the 2002 Nobel Prize in Chemistry awarded to researcher Koichi Tanaka for soft laser desorption ionization. Its instruments regularly win R&D 100 awards and Analytical Scientist innovation rankings. Corporate recognition includes consistent high placement in Japanese employer and reputation surveys and a fifth consecutive year of record net sales in fiscal 2025.
Controversy, Regulation & Public Scrutiny
Shimadzu has no material corporate scandals or major regulatory penalties on recent public record. As a medical device and defense-component manufacturer it operates under continuous regulatory compliance in multiple jurisdictions, and its history contains no widely reported product recalls or conduct controversies of significance.
Brands Owned by Shimadzu Corporation
Shimadzu Corporation owns 1 brand in our database. Explore the ownership tree below — click categories to expand and see individual brands.
Shimadzu Corporation
public · Founded 1875 · Kyoto, Kyoto, Japan
1
brands
Stock Information
Shimadzu Corporation Ownership: Pros & Cons
Advantages
- +Public listing funds sustained R&D and global service expansion
- +Diversified four-segment model spreads cyclical exposure
- +Installed-base consumables and service revenue adds recurring income
- +Net cash balance sheet supports investment without leverage
- +150-year credibility and Nobel-linked scientific reputation
Considerations
- -Capital-equipment cycles create uneven order timing
- -Chinese domestic instrument makers are compressing mid-tier pricing
- -Yen volatility distorts consolidated overseas revenue
- -Medical imaging competes against much larger multinationals
- -Defense and semiconductor exposure adds geopolitical sensitivity
Frequently Asked Questions About Shimadzu Corporation
Who owns Shimadzu Corporation?
It is publicly owned through its listing on the Tokyo Stock Exchange, code 7701. Shareholders are institutional investors, trust banks, foreign funds, and individuals; no family or single holder controls it.
Is Shimadzu Corporation publicly traded?
Yes. It has long been listed on the Tokyo Stock Exchange and publishes quarterly consolidated results under Japanese GAAP.
What does Shimadzu Corporation make?
Analytical and measuring instruments such as chromatographs and mass spectrometers, medical X-ray and imaging systems, industrial machinery including turbomolecular pumps, and aircraft equipment.
When was Shimadzu founded?
In March 1875 in Kyoto by Genzo Shimadzu, originally to produce physics and chemistry educational instruments. It incorporated as a limited company in 1917 and marked its 150th anniversary in 2025.
How large is Shimadzu?
Fiscal 2025 consolidated net sales were 560.7 billion yen, about $3.6 billion, with 14,649 group employees and 77 subsidiaries worldwide as of March 2026.
Did Shimadzu win a Nobel Prize?
An employee did. Engineer Koichi Tanaka shared the 2002 Nobel Prize in Chemistry for soft laser desorption ionization, the technology behind MALDI-TOF mass spectrometry.








